Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: Stock Watcher who wrote (19603)	11/22/1999 10:24:00 AM
From: RCJIII	Read Replies (1) \| Respond to of 52051

CIMA gets another strong buy recommendation, $18 price target. (REUTERS) RESEARCH ALERT - Cima Labs <CIMA.O> Q4 profit seen RESEARCH ALERT - Cima Labs <CIMA.O> Q4 profit seen NEW YORK, Nov 22 (Reuters) - Fahnestock & Co. Inc. said Monday that it expects Cima Labs Inc. to turn profitable during the fourth quarter of 1999. -- stock rated speculative buy. -- year-end 2001 price target is $18. -- estimates Q4 1999 earnings per share $0.02. -- estimates 1999 loss per share $0.13. -- estimates 2000 earnings per share $0.35. -- estimates 2001 EPS $0.80. -- sees turning profitable during Q4 due to a license payment from Organon Inc. -- sees profitable first quarter of 2000 on an operating basis. -- sees potential for price appreciation as company receives growing royalties form its collaborative partners Novartis, AstraZeneca and Organon. -- notes company has a rapidly dissolving oral drug delivery technology (OraSolv) that features prominently in several important products. ((-- New York Health Desk 212 859-1870))